Recent BioUtah News & Events

Wykoff to build upon more than two decades of public and private sector healthcare leadership to head up delivering Nomi Health’s core business offerings

Congress is expected to vote this week on a massive omnibus government funding bill that would run through the end of the 2023 fiscal year. The legislative text was released on Tuesday. The $1.7 trillion, 4,155-page bill includes a number of significant healthcare provisions. Of particular interest to the life sciences industry are provisions included […]

IONIQ is “Clinical Diagnostics Solution of the Year 2022”

For IONIQ Sciences, 2022 was another big year. As we respond to the FDA’s substantive review of our De Novo application for the ‘breakthrough‘ IONIQ ProLung Test, powerful macroeconomic factors are highlighting the importance of early cancer detection. Despite uncertain conditions in the financial market, we have a compelling message for potential institutional and strategic investors at […]

The 2022 TEConomy/BIO report, The US Bioscience Industry: Fostering Innovation and Driving America’s Economy Forward, examines the bioscience industry’s impact on the national economy and provides state specific data, with Utah and its major metropolitan areas ranking high in specialized employment concentration in three major subsectors – medical device manufacturing, pharmaceuticals, research, testing and medical laboratories […]

The annual Life Sciences Day on the Hill provides our industry with the opportunity to get face time with legislators and other government officials during the 2023 legislative session. Slated for Friday, January 27, 2023 from 11:00 AM to 2:00 PM, the event permits BioUtah members to demonstrate their important breakthroughs, devices and innovations. It […]

Stryker, one of the world’s leading medical technology companies, recently opened its Neurovascular (NV) lab, a state-of-the-art lab designed to accelerate stroke-related innovation in Asia Pacific. Located within the Stryker Global Technology Center (SGTC) at International Park, Gurgaon, India, the Keystone Suite will enable collaboration between customers, product development engineers, cross-functional teams, and other key […]

Cambridge, MA, November 9, 2022 /Business Wire/ – Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] announced that Ipsen, SA (“Ipsen”) issued a press release today reporting its primary analysis of the results of its Phase III NAPOLI 3 trial of Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) as a […]

Exhibiting their innovative products and services to over 80,000 visitors, 11 life science companies represented Utah at the MEDICA trade show in Düsseldorf, Germany. Looking across the global landscape of innovative healthcare products, Charlotte Serage, WTC Utah’s manager of trade shows and trade missions, said, “It’s clear that Utah is a major player.” Shoutout to EVŌQbio, Matia Mobility, NanoSpot.ai, SINTX […]

SALT LAKE CITY–(BUSINESS WIRE)–Halia Therapeutics, a clinical stage biopharmaceutical company advancing innovative medicines to treat diseases driven by chronic inflammation, was invited to present today at the 4th Inflammasome Therapeutics Summit. Dr. David J. Bearss, CEO of Halia Therapeutics, will chair a panel entitled, “Advances in Proof-of-Concept Trials & Moving Towards the Clinic,” and also […]

LONDON and SALT LAKE CITY, Nov. 30, 2022 (GLOBE NEWSWIRE) — Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal first quarter ended September 30, 2022. Recent […]

by Julie A. Vetalice Ortho Development BKS Total PSI has been released for commercial distribution in the United States in collaboration with Materialise, a provider of additive manufacturing software and 3D printing solutions. BKS Total PSI is compatible with Ortho Development’s BKS and BKS TriMax total knee replacement systems. BKS Total PSI, powered by Materialise, […]

Sumitomo Pharma Oncology to Present Preliminary Clinical Data Evaluating Investigational Agent TP-3654

On November 17, Sen. Mike Lee (R-UT) introduced the “Biosimilar Red Tape Elimination Act” to increase patient access to biosimilars and reduce costs by easing switching studies required to allow a biosimilar to be substituted for a biologic. View a one-page summary HERE. Currently, pharmacists can substitute generics in lieu of their branded counterparts without […]

The University of Utah Health has launched NEW DIGITAL HEALTH INITIATIVE

Kåre Schultz to Retire After a Transformative Five-Year Tenure Setting the Stage for an Exciting Future

SALT LAKE CITY, Nov. 10, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of UroSuite, a comprehensive suite of genetic risk assessment tests that cover every stage of prostate cancer care. UroSuite includes Myriad’s Prolaris® Prostate Cancer Test, MyRisk™ Hereditary Cancer Test, […]

CenExel announces a new Clinical Sciencesbusiness unit and more.

On Thursday, November 10, 2022, the BioHIve gathered at the Salt Palace for the annual BioHive Summit presented by Mayer Brown. It was the first time in three years the industry had gathered in person. The pent up demand for in-person networking combined with quality programming resulted in record registration of over 700 participants. Governor […]

Betty Iverson Retirement Announced

PolarityTE provided a business update and reported financial results for the quarterly period ended September 30, 2022.

PolarityTE confirmed that on November 1, 2022, it received an unsolicited, non-binding offer (followed by an amended offer on November 8, 2022) from Michael Brauser to acquire all of the outstanding common stock of the Company not owned by him for $1.25 per share in cash.

Clene announced that it has entered into a securities purchase agreement with certain existing stockholders.

The primary endpoint of adjusted ALSFRS-R and secondary endpoints of CAFS and SVC were not met at 24 weeks Prespecified exploratory analyses of the secondary survival endpoint for the 30 mg dose demonstrated a >90% reduction in risk of death or risk of death/permanently assisted ventilation at 24 weeks Survival signal consistent with prior results […]